Cell Therapy in Human and Veterinary Medicine: A One Health Perspective on Historical Evolution and European Regulatory Frameworks
Biomolecules · 10.11.2026 · 16 (11) · 1641
DOI: 10.3390/biom16111641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 10.11.2026. Verfasst von Jesús I. Gil-Chinchilla und 10 weiteren Autor:innen. Die Arbeit nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union.
Abstract (Originalsprache)
Cell therapy has evolved from early interventions based on living cell transfer to become a complex and heterogeneous field that now includes cell-based advanced therapy products, programmable immunotherapies, and cell-derived acellular products. This narrative review examines the historical, translational, and regulatory development of cell therapy from a One Health perspective, integrating human and veterinary medicine. We discuss key milestones, including transfusion medicine, the stem cell concept, the transplantation of haematopoietic stem cells (HSCs), the expansion of mesenchymal stem/stromal cells (MSCs), the development of induced pluripotent stem cells (iPSCs), and the secretome, including extracellular vesicles (EVs). Rather than following a linear trajectory, we examine overlapping developments in regenerative and immunomodulatory approaches and in cellular immunotherapies, including programmable strategies. We contrast the established regulatory pathways, standardisation, and industrial manufacturing of advanced therapy medicinal products (ATMPs) in human medicine with the more recent and heterogeneous development of veterinary cell-based therapies, particularly in non-industrial settings. Together, these differences illustrate how product definition, manufacturing models, clinical evidence generation and non-industrial use shape the regulatory translation of cell-based and acellular therapies. By linking historical milestones with translational and regulatory differences, this review provides a framework for understanding cell-based and cell-derived therapies across human and veterinary medicine.
Förderung
- Instituto de Salud Carlos III
- European Union
Zitieren
APA
Gil-Chinchilla, J. I., Talavera-López, J., Marín-Atucha, N. T., Casado, S., Blanquer, M., García-Hernández, A. M., Fernández-Santos, M. E., Sancho-López, A., Avendaño-Solá, C., Moraleda, J. M., & García-Bernal, D. (2026). Cell Therapy in Human and Veterinary Medicine: A One Health Perspective on Historical Evolution and European Regulatory Frameworks. Biomolecules, 16(11), 1641. https://doi.org/10.3390/biom16111641
Vancouver
Gil-Chinchilla JI, Talavera-López J, Marín-Atucha NT, Casado S, Blanquer M, García-Hernández AM, et al. Cell Therapy in Human and Veterinary Medicine: A One Health Perspective on Historical Evolution and European Regulatory Frameworks. Biomolecules. 2026;16(11):1641. doi:10.3390/biom16111641
BibTeX
@article{GilChinchilla2026,
author = {Gil-Chinchilla, Jesús I. and Talavera-López, Jesús and Marín-Atucha, Noemi T. and Casado, Susana and Blanquer, Miguel and García-Hernández, Ana M. and Fernández-Santos, María Eugenia and Sancho-López, Aránzazu and Avendaño-Solá, Cristina and Moraleda, Jose M. and García-Bernal, David},
title = {Cell Therapy in Human and Veterinary Medicine: A One Health Perspective on Historical Evolution and European Regulatory Frameworks},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1641},
doi = {10.3390/biom16111641}
}
EUVIMED